To reduce toxicity associated with external ␥-beam radiation, we investigated radioimmunotherapy with an anti-CD45 mAb labeled with the ␣-emitter, astatine-211 (
IntroductionWith the introduction of nonmyeloablative preparative regimens, allogeneic hematopoietic cell transplantation (HCT) has become a curative treatment option for a variety of malignant hematologic diseases in older and medically infirm patients. However, treatmentrelated toxicity and relapse are still major causes of morbidity and mortality. In an effort to increase the radiation dose delivered to the target organs while further reducing the late toxic effects of external beam ␥-irradiation, strategies using radioimmunotherapy (RIT) targeted toward hematopoietic tissues as a part of the conditioning regimen have been investigated. The efficacy and safety of this approach have been demonstrated in several clinical trials where antibody-coupled -emitters, such as yttrium-90 ( 90 Y), rhenium-188 ( 188 Re), and iodine-131 ( 131 I), have been used to augment a variety of high-dose and reduced-intensity conditioning regimens. [1][2][3][4] The long path length of -emitters, which makes them ideal in the setting of poorly perfused or bulky tumors, also makes them less optimal in situations with small volume tumors, minimal residual disease, or as part of an HCT conditioning regimen. 5 It has been estimated that only 1.5% and 17% of the energy from 90 Y-and 131 I-labeled mAbs, respectively, is deposited in tumors that are 200 m in diameter, whereas the rest is deposited in surrounding tissue resulting in nonspecific toxicity. 6 Alternative sources of radiation are available from the ␣-particle-emitting radionuclides. ␣-particles are characterized by short path lengths of 40 to 90 m in vivo, limiting the off-target toxicity to a few cell diameters. Furthermore, ␣-particles are more cytotoxic and have superior relative biologic effectiveness than -particles because of a 400-fold greater linear energy transfer and the limited ability of tumor cells to repair ␣-particle-induced DNA damage. [7][8][9] Apart from our own preclinical experiences with the ␣-emitter bismuth-213 ( 213 Bi), the use of an ␣-emitter for RIT alone as conditioning in HCT has not been explored. We have previously demonstrated that 213 Bi-labeled mAb targeted toward the pan-hematopoietic antigen, CD45, or the T-cell receptor ␣ (TCR␣) could replace 200 to 300 cGy total body irradiation (TBI) as nonmyeloablative conditioning in dog leukocyte antigen (DLA)-identical or haploidentical bone marrow transplantation. [10][11][12][13] Although the treatment was successful in allowing sustained engraftment with minimal toxicity, obstacles, including short half-life (45.6 minutes), limited availability, and high cost of 213 Bi, made the translation of 213 Bi-labeled mAb into clinical studies impractical. Astatine-211 ( 211 At; t 1/2 ϭ 7.21 hours) is an alternative ␣-particle-emitting isotope. The advantage of 211 At is that it is available in quantities that can be scaled up for clinical stud...